Anti-CGA monoclonal antibody, clone 5A5

The Flos Lonicerae Japonicae (FLJ), Lonicera japonica Thunb, belonging to the Caprifoliaceae family, is an economically important plant that is highly utilized in traditional Chinese medicine as well as in Japanese medicine. The flowers of these plants are rich in chlorogenic acid (CGA) and luteoloside. Our previous study revealed that tetraploid L. japonica has higher fresh/dry weight, phenolic acids and flavonoids contents than those of diploid plants. However, why tetraploid L. japonica can yield higher CGA and luteolosides than that in diploid and what is the difference in the molecular regulatory mechanism of these pathways between diploid and tetraploids remained unclear. Therefore, in the present study, we performed comprehensive transcriptome analyses of different flowering stages of diploid and tetraploid L. japonica. The CGA content of tetraploid was found higher than that of diploid at all the growth stages. While the luteoloside content of diploid was higher than that of tetraploid at S4 and S6 growth stages. We obtained a high-quality transcriptome assembly (N50 = 2,055 bp; Average length = 1,331 bp) compared to earlier studies. Differential expression analysis revealed that several important genes involving in plant hormone signal transduction, carbon metabolism, starch/sucrose metabolism and plant-pathogen interaction were upregulated in tetraploid compared with the diploid L. japonica, reflecting the higher adaptability and resistance of tetraploid species. Furthermore, by associating the phenotypic data and gene expression profiles, we were able to characterize the potential molecular regulatory mechanism of important biosynthetic pathways at different flowering stages. Overall, our work provides a foundation for further research on these important secondary metabolite pathways and their implications in traditional Chinese/Japanese medicine.

Introduction: Intensive treatments can often not be administered to elderly patients with esophageal squamous cell carcinoma (ESCC), leading to a poorer prognosis. This multi-center phase II trial aimed to determine the toxicity profile and efficiency of S-1-based simultaneous integrated boost radiotherapy (SIB-RT) followed by consolidation chemotherapy with S-1 in elderly ESCC patients and to evaluate the usefulness of comprehensive geriatric assessment (CGA). Patients and Methods: We prospectively enrolled 46 elderly patients (age >= 70 years) with histopathologically proven ESCC. The patients underwent pretreatment CGA followed by SIB-RT (dose, 59.92 Gy/50.4 Gy) in 28 daily fractions administered using intensity-modulated radiotherapy or volumetric-modulated arc therapy. S-1 was orally administered (40-60 mg/m(2)) concurrently with radiotherapy and 4-8 weeks later, for up to four 3-week cycles at the same dose. Results: The median survival time was 22.6 months. The 1- and 2-year overall survival rates were 80.4 and 47.8%, respectively. The overall response rate was 78.3% (36/46). The incidence of grade 3-4 toxicities was 28% (13/46). The most common grade 3-4 toxicities were radiation esophagitis (5/46, 10.9%), nausea (4/46, 8.7%), anorexia (3/46, 6.5%), and radiation pneumonitis (3/46, 6.5%). There were no grade 5 toxicities. CGA identified that 48.8% of patients were at risk for depression and 65.5% had malnutrition. Conclusion: Concurrent S-1 treatment with SIB-RT followed by 4 cycles of S-1 monotherapy yielded satisfactory tumor response rates and manageable toxicities in selected elderly patients with ESCC. Pretreatment CGA uncovered numerous health problems and allowed the provision of appropriate supportive care.